Skip to main content
Top
Published in: Archives of Gynecology and Obstetrics 6/2012

01-06-2012 | Gynecologic Oncology

Increasing fear of adverse effects drops intention to vaccinate after the introduction of prophylactic HPV vaccine

Authors: Alexandros Sotiriadis, Themistoklis Dagklis, Vaia Siamanta, Konstantinos Chatzigeorgiou, Theodoros Agorastos, The LYSISTRATA Study Group

Published in: Archives of Gynecology and Obstetrics | Issue 6/2012

Login to get access

Abstract

Purpose

The purpose of this study was (1) to explore for socio-demographic factors that could potentially affect the intention of women to vaccinate themselves, their 13-year-old daughter and their 13-year-old son against HPV, and (2) to investigate the main reasons for declining vaccination.

Methods

A structured questionnaire was used in participants of the project (N = 5,249). Logistic regression analysis was applied in order to examine the correlation between vaccine acceptability and a list of potential predictors. In women declining vaccination, the reported reasons for decline were analyzed.

Results

Residence in rural areas and low to medium tiers of family income were the most constant factors in favor of intention to vaccinate. Receiving information from a healthcare professional was found to positively affect vaccine acceptability for the woman herself, but it did not affect her intention to vaccinate her daughter or her son. The acceptance rates decreased significantly after the vaccine became available, both for the women themselves and for their daughters or sons. During the same year, a shift was noted in the reason for declining vaccination; the self-perception of insufficient knowledge significantly decreased and the fear of adverse effects significantly increased in all three cases.

Conclusion

Apart from demographic factors which may favor or disfavor vaccine acceptability, the intention to vaccinate decreased significantly and the proportion of women rejecting vaccination for safety concerns increased significantly after the introduction of the vaccine, coinciding with isolated cases of negative publicity and highlighting the potential of misinformation by the media.
Appendix
Available only for authorised users
Literature
1.
go back to reference Quinn M, Babb P, Jones J, Allen E (1999) Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. BMJ 318:904–908PubMedCrossRef Quinn M, Babb P, Jones J, Allen E (1999) Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. BMJ 318:904–908PubMedCrossRef
2.
go back to reference Hakama M, Chamberlain J, Day NE, Miller AB, Prorok PC (1985) Evaluation of screening programmes for gynaecological cancer. Br J Cancer 52:669–673PubMedCrossRef Hakama M, Chamberlain J, Day NE, Miller AB, Prorok PC (1985) Evaluation of screening programmes for gynaecological cancer. Br J Cancer 52:669–673PubMedCrossRef
3.
go back to reference Arbyn M, Castellsague X, de Sanjose S, Bruni L, Saraiya M et al (2011) Worldwide burden of cervical cancer in 2008. Ann Oncol 22:2675–2686PubMedCrossRef Arbyn M, Castellsague X, de Sanjose S, Bruni L, Saraiya M et al (2011) Worldwide burden of cervical cancer in 2008. Ann Oncol 22:2675–2686PubMedCrossRef
4.
go back to reference Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA et al (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12–19PubMedCrossRef Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA et al (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12–19PubMedCrossRef
5.
go back to reference Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J et al (2006) High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95:1459–1466PubMedCrossRef Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J et al (2006) High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95:1459–1466PubMedCrossRef
6.
go back to reference Ault KA (2007) Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369:1861–1868PubMedCrossRef Ault KA (2007) Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369:1861–1868PubMedCrossRef
7.
go back to reference Watson M, Shaw D, Molchanoff L, McInnes C (2009) Challenges, lessons learned and results following the implementation of a human papilloma virus school vaccination program in South Australia. Aust N Z J Public Health 33:365–370PubMedCrossRef Watson M, Shaw D, Molchanoff L, McInnes C (2009) Challenges, lessons learned and results following the implementation of a human papilloma virus school vaccination program in South Australia. Aust N Z J Public Health 33:365–370PubMedCrossRef
8.
go back to reference Berry-Caban CS, Buenaventura JB (2009) HPV vaccination coverage among adolescents aged 9 to 17 years in a United States military treatment facility. Int J Adolesc Med Health 21:567–570PubMedCrossRef Berry-Caban CS, Buenaventura JB (2009) HPV vaccination coverage among adolescents aged 9 to 17 years in a United States military treatment facility. Int J Adolesc Med Health 21:567–570PubMedCrossRef
9.
go back to reference Rouzier R, Giordanella JP (2010) Coverage and compliance of Human Papilloma Virus vaccines in Paris: demonstration of low compliance with non-school-based approaches. J Adolesc Health 47:237–241PubMedCrossRef Rouzier R, Giordanella JP (2010) Coverage and compliance of Human Papilloma Virus vaccines in Paris: demonstration of low compliance with non-school-based approaches. J Adolesc Health 47:237–241PubMedCrossRef
10.
go back to reference Dempsey AF, Zimet GD, Davis RL, Koutsky L (2006) Factors that are associated with parental acceptance of human papillomavirus vaccines: a randomized intervention study of written information about HPV. Pediatrics 117:1486–1493PubMedCrossRef Dempsey AF, Zimet GD, Davis RL, Koutsky L (2006) Factors that are associated with parental acceptance of human papillomavirus vaccines: a randomized intervention study of written information about HPV. Pediatrics 117:1486–1493PubMedCrossRef
11.
go back to reference Muñoz N, Manalastas R Jr, Pitisuttithum P, Tresukosol D et al (2009) Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. Lancet 373:1949–1957PubMedCrossRef Muñoz N, Manalastas R Jr, Pitisuttithum P, Tresukosol D et al (2009) Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. Lancet 373:1949–1957PubMedCrossRef
12.
go back to reference Jain N, Euler GL, Shefer A, Lu P, Yankey D et al (2009) Human papillomavirus (HPV) awareness and vaccination initiation among women in the United States, National Immunization Survey-Adult 2007. Prev Med 48:426–431PubMedCrossRef Jain N, Euler GL, Shefer A, Lu P, Yankey D et al (2009) Human papillomavirus (HPV) awareness and vaccination initiation among women in the United States, National Immunization Survey-Adult 2007. Prev Med 48:426–431PubMedCrossRef
13.
go back to reference Chao C, Velicer C, Slezak JM, Jacobsen SJ (2010) Correlates for human papillomavirus vaccination of adolescent girls and young women in a managed care organization. Am J Epidemiol 171:357–367PubMedCrossRef Chao C, Velicer C, Slezak JM, Jacobsen SJ (2010) Correlates for human papillomavirus vaccination of adolescent girls and young women in a managed care organization. Am J Epidemiol 171:357–367PubMedCrossRef
14.
go back to reference Pruitt SL, Schootman M (2010) Geographic disparity, area poverty, and human papillomavirus vaccination. Am J Prev Med 38:525–533PubMedCrossRef Pruitt SL, Schootman M (2010) Geographic disparity, area poverty, and human papillomavirus vaccination. Am J Prev Med 38:525–533PubMedCrossRef
15.
go back to reference Kwon Y, Cho HY, Lee YK, Bae GR, Lee SG (2010) Relationship between intention of novel influenza A (H1N1) vaccination and vaccination coverage rate. Vaccine 29:161–165PubMedCrossRef Kwon Y, Cho HY, Lee YK, Bae GR, Lee SG (2010) Relationship between intention of novel influenza A (H1N1) vaccination and vaccination coverage rate. Vaccine 29:161–165PubMedCrossRef
16.
go back to reference (No authors listed) (2010) Interim results: state-specific influenza A (H1N1) 2009 monovalent vaccination coverage—United States, October 2009–January 2010. MMWR Morb Mortal Wkly Rep 59:363–368 (No authors listed) (2010) Interim results: state-specific influenza A (H1N1) 2009 monovalent vaccination coverage—United States, October 2009–January 2010. MMWR Morb Mortal Wkly Rep 59:363–368
17.
go back to reference Constantine NA, Jerman P (2007) Acceptance of human papillomavirus vaccination among Californian parents of daughters: a representative statewide analysis. J Adolesc Health 40:108–115PubMedCrossRef Constantine NA, Jerman P (2007) Acceptance of human papillomavirus vaccination among Californian parents of daughters: a representative statewide analysis. J Adolesc Health 40:108–115PubMedCrossRef
18.
go back to reference (No authors listed) (2009) Intent to receive influenza A (H1N1) 2009 monovalent and seasonal influenza vaccines—two counties, North Carolina, August 2009. MMWR Morb Mortal Wkly Rep 58:1401–1405 (No authors listed) (2009) Intent to receive influenza A (H1N1) 2009 monovalent and seasonal influenza vaccines—two counties, North Carolina, August 2009. MMWR Morb Mortal Wkly Rep 58:1401–1405
19.
go back to reference Eastwood K, Durrheim DN, Jones A, Butler M (2010) Acceptance of pandemic (H1N1) 2009 influenza vaccination by the Australian public. Med J Aust 192:33–36PubMed Eastwood K, Durrheim DN, Jones A, Butler M (2010) Acceptance of pandemic (H1N1) 2009 influenza vaccination by the Australian public. Med J Aust 192:33–36PubMed
20.
go back to reference Hoover DR, Carfioli B, Moench EA (2000) Attitudes of adolescent/young adult women toward human papillomavirus vaccination and clinical trials. Health Care Women Int 21:375–391PubMedCrossRef Hoover DR, Carfioli B, Moench EA (2000) Attitudes of adolescent/young adult women toward human papillomavirus vaccination and clinical trials. Health Care Women Int 21:375–391PubMedCrossRef
21.
go back to reference Boehner CW, Howe SR, Bernstein DI, Rosenthal SL (2003) Viral sexually transmitted disease vaccine acceptability among college students. Sex Transm Dis 30:774–778PubMedCrossRef Boehner CW, Howe SR, Bernstein DI, Rosenthal SL (2003) Viral sexually transmitted disease vaccine acceptability among college students. Sex Transm Dis 30:774–778PubMedCrossRef
22.
go back to reference Kahn JA, Rosenthal SL, Hamann T, Bernstein DI (2003) Attitudes about human papillomavirus vaccine in young women. Int J STD AIDS 14:300–306PubMedCrossRef Kahn JA, Rosenthal SL, Hamann T, Bernstein DI (2003) Attitudes about human papillomavirus vaccine in young women. Int J STD AIDS 14:300–306PubMedCrossRef
23.
go back to reference Slomovitz BM, Sun CC, Frumovitz M, Soliman PT, Schmeler KM et al (2006) Are women ready for the HPV vaccine? Gynecol Oncol 103:151–154PubMedCrossRef Slomovitz BM, Sun CC, Frumovitz M, Soliman PT, Schmeler KM et al (2006) Are women ready for the HPV vaccine? Gynecol Oncol 103:151–154PubMedCrossRef
24.
go back to reference Cook RL, Zhang J, Mullins J, Kauf T, Brumback B et al (2010) Factors associated with initiation and completion of human papillomavirus vaccine series among young women enrolled in Medicaid. J Adolesc Health 47:596–599PubMedCrossRef Cook RL, Zhang J, Mullins J, Kauf T, Brumback B et al (2010) Factors associated with initiation and completion of human papillomavirus vaccine series among young women enrolled in Medicaid. J Adolesc Health 47:596–599PubMedCrossRef
25.
go back to reference Cui Y, Baldwin SB, Wiley DJ, Fielding JE (2010) Human papillomavirus vaccine among adult women: disparities in awareness and acceptance. Am J Prev Med 39:559–563PubMedCrossRef Cui Y, Baldwin SB, Wiley DJ, Fielding JE (2010) Human papillomavirus vaccine among adult women: disparities in awareness and acceptance. Am J Prev Med 39:559–563PubMedCrossRef
26.
go back to reference Gamble HL, Klosky JL, Parra GR, Randolph ME (2010) Factors influencing familial decision-making regarding human papillomavirus vaccination. J Pediatr Psychol 35:704–715PubMedCrossRef Gamble HL, Klosky JL, Parra GR, Randolph ME (2010) Factors influencing familial decision-making regarding human papillomavirus vaccination. J Pediatr Psychol 35:704–715PubMedCrossRef
27.
go back to reference Kang HS, Moneyham L (2011) Attitudes, intentions, and perceived barriers to human papillomavirus vaccination among Korean high school girls and their mothers. Cancer Nurs 34:202–208PubMedCrossRef Kang HS, Moneyham L (2011) Attitudes, intentions, and perceived barriers to human papillomavirus vaccination among Korean high school girls and their mothers. Cancer Nurs 34:202–208PubMedCrossRef
28.
go back to reference Sundstrom K, Tran TN, Lundholm C, Young C, Sparen P et al (2010) Acceptability of HPV vaccination among young adults aged 18–30 years—a population based survey in Sweden. Vaccine 28:7492–7500PubMedCrossRef Sundstrom K, Tran TN, Lundholm C, Young C, Sparen P et al (2010) Acceptability of HPV vaccination among young adults aged 18–30 years—a population based survey in Sweden. Vaccine 28:7492–7500PubMedCrossRef
29.
go back to reference Zimet GD, Weiss TW, Rosenthal SL, Good MB, Vichnin MD (2010) Reasons for non-vaccination against HPV and future vaccination intentions among 19–26 year-old women. BMC Womens Health 10:27PubMed Zimet GD, Weiss TW, Rosenthal SL, Good MB, Vichnin MD (2010) Reasons for non-vaccination against HPV and future vaccination intentions among 19–26 year-old women. BMC Womens Health 10:27PubMed
30.
go back to reference Dempsey A, Cohn L, Dalton V, Ruffin M (2011) Worsening disparities in HPV vaccine utilization among 19–26 year old women. Vaccine 29:528–534PubMedCrossRef Dempsey A, Cohn L, Dalton V, Ruffin M (2011) Worsening disparities in HPV vaccine utilization among 19–26 year old women. Vaccine 29:528–534PubMedCrossRef
31.
go back to reference Lower J (2008) Two unclear cases of death. Can we still recommend HPV vaccination? MMW Fortschr Med 150:6PubMed Lower J (2008) Two unclear cases of death. Can we still recommend HPV vaccination? MMW Fortschr Med 150:6PubMed
33.
go back to reference Bakogianni GD, Nikolakopoulos KM, Nikolakopoulou NM (2010) HPV vaccine acceptance among female Greek students. Int J Adolesc Med Health 22:271–273PubMedCrossRef Bakogianni GD, Nikolakopoulos KM, Nikolakopoulou NM (2010) HPV vaccine acceptance among female Greek students. Int J Adolesc Med Health 22:271–273PubMedCrossRef
34.
go back to reference Agorastos T, Chatzigeorgiou K, Brotherton JM, Garland SM (2009) Safety of human papillomavirus (HPV) vaccines: a review of the international experience so far. Vaccine 27:7270–7281PubMedCrossRef Agorastos T, Chatzigeorgiou K, Brotherton JM, Garland SM (2009) Safety of human papillomavirus (HPV) vaccines: a review of the international experience so far. Vaccine 27:7270–7281PubMedCrossRef
35.
go back to reference Pomfret TC, Gagnon JM Jr, Gilchrist AT (2011) Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics. J Clin Pharm Ther 36:1–9PubMedCrossRef Pomfret TC, Gagnon JM Jr, Gilchrist AT (2011) Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics. J Clin Pharm Ther 36:1–9PubMedCrossRef
36.
go back to reference Conroy K, Rosenthal SL, Zimet GD, Jin Y, Bernstein DI et al (2009) Human papillomavirus vaccine uptake, predictors of vaccination, and self-reported barriers to vaccination. J Womens Health (Larchmt) 18:1679–1686CrossRef Conroy K, Rosenthal SL, Zimet GD, Jin Y, Bernstein DI et al (2009) Human papillomavirus vaccine uptake, predictors of vaccination, and self-reported barriers to vaccination. J Womens Health (Larchmt) 18:1679–1686CrossRef
37.
go back to reference Bernard DM, Cooper Robbins SC, McCaffery KJ, Scott CM, Skinner SR (2011) The domino effect: adolescent girls’ response to human papillomavirus vaccination. Med J Aust 194:297–300PubMed Bernard DM, Cooper Robbins SC, McCaffery KJ, Scott CM, Skinner SR (2011) The domino effect: adolescent girls’ response to human papillomavirus vaccination. Med J Aust 194:297–300PubMed
38.
go back to reference Hilton S, Hunt K, Langan M, Bedford H, Petticrew M (2010) Newsprint media representations of the introduction of the HPV vaccination programme for cervical cancer prevention in the UK (2005–2008). Soc Sci Med 70:942–950PubMedCrossRef Hilton S, Hunt K, Langan M, Bedford H, Petticrew M (2010) Newsprint media representations of the introduction of the HPV vaccination programme for cervical cancer prevention in the UK (2005–2008). Soc Sci Med 70:942–950PubMedCrossRef
39.
go back to reference Habel MA, Liddon N, Stryker JE (2009) The HPV vaccine: a content analysis of online news stories. J Womens Health (Larchmt) 18:401–407CrossRef Habel MA, Liddon N, Stryker JE (2009) The HPV vaccine: a content analysis of online news stories. J Womens Health (Larchmt) 18:401–407CrossRef
40.
go back to reference Keelan J, Pavri V, Balakrishnan R, Wilson K (2010) An analysis of the Human Papilloma Virus vaccine debate on MySpace blogs. Vaccine 28:1535–1540PubMedCrossRef Keelan J, Pavri V, Balakrishnan R, Wilson K (2010) An analysis of the Human Papilloma Virus vaccine debate on MySpace blogs. Vaccine 28:1535–1540PubMedCrossRef
Metadata
Title
Increasing fear of adverse effects drops intention to vaccinate after the introduction of prophylactic HPV vaccine
Authors
Alexandros Sotiriadis
Themistoklis Dagklis
Vaia Siamanta
Konstantinos Chatzigeorgiou
Theodoros Agorastos
The LYSISTRATA Study Group
Publication date
01-06-2012
Publisher
Springer-Verlag
Published in
Archives of Gynecology and Obstetrics / Issue 6/2012
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-011-2208-z

Other articles of this Issue 6/2012

Archives of Gynecology and Obstetrics 6/2012 Go to the issue